Embody vs Hims: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 15, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Hims scores higher on our rubric, 7.9/10 against 7.3/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit Embody - from $69/mo →or find your match

Hims beats Embody overall, scoring 7.9/10 vs 7.3/10. Published pricing is not a like-for-like monthly comparison: Embody is from $69/mo; Hims is $188 first month, then $298/mo. Choose Embody for people who want the oral tirzepatide gum, or who are comfortable selecting a 4-, 12-, 24- or 52-week plan for an advertised glp-1 + gip rate from $129. Choose Hims for men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors.

A side-by-side look at Embody and Hims to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Embody

#32 of 54

7.3/10

Online weight-loss program that ships compounded GLP-1 medication to your door. Modern Metabolic Medicine, Inc. runs the storefront and OpenLoop Health supplies the clinical network on the current site. Embody now advertises compounded semaglutide from $79 and GLP-1 + GIP from $129; its FAQ says the chosen rate holds within a selected 4-, 12-, 24- or 52-week plan. Its standout is oral tirzepatide gum for people who do not want injections.

Visit Embody

Higher Rated

Hims

#7 of 54

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy, Ozempic, Foundayo, and Zepbound paths and has since exited compounded semaglutide for new retail patients. The advertised medication floor is $149, but the required Weight Loss Membership adds $39 in month one and $149/month after that, so the all-in floor is $188 initially and $298 ongoing before any product- or dose-specific increase. Its parent still reports offering access to compounded GLP-1 medications on a limited scale (Q2 2026 results, filed with the SEC August 10, 2026). Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.

Visit Hims

Feature	Embody	Hims
Why each one	One of the few GLP-1 providers offering oral tirzepatide as a chewable gum, a real choice for people who don't want injections.	The only publicly-traded men's telehealth (NYSE: HIMS) with FDA-approved Wegovy via direct Novo Nordisk partnership. Brand-name access plus SEC accountability, but balanced against a 3.0 Trustpilot rating that lags peers.
Our Score	7.3/10	7.9/10
Headline Price	from $69/mo	$188 first month, then $298/mo
Medication Type	Compounded	Brand
Insurance Accepted	No	No
Best For	People who want the oral tirzepatide gum, or who are comfortable selecting a 4-, 12-, 24- or 52-week plan for an advertised GLP-1 + GIP rate from $129	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors
Watch out for	Runs two sibling storefronts most shoppers will never connect to it: SnagRx (snagrx.com) and RodeoMeds (rodeomeds.com) are the same legal entity, Modern Metabolic Medicine, Inc. SnagRx still advertises a separate $69/$119 promotion; Embody now advertises $79/$129 under its own plan menu. Neither site tells shoppers they share an operator. See our [SnagRx review](/reviews/snagrx)	Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.
Ranking	#32	#7
Get started	Visit Embody	Visit Hims

Pros & Cons Compared

Embody

Pros

+Oral tirzepatide gum is rare. Real option for needle-phobic users. (How well it absorbs vs the FDA-approved injection isn't published.)
+Advertised injection floors of $79 for semaglutide and $129 for GLP-1 + GIP, verified August 14, 2026. The FAQ says the selected rate holds within the chosen plan.
+Four plan lengths are disclosed (4, 12, 24 and 52 weeks), giving shoppers a shorter-term option as well as longer-plan pricing.
+100% money-back guarantee in writing: if you follow the program and don't see results in 6 months, they say they'll make it right.
+Replies to every negative Trustpilot review, usually within 24 hours.

Cons

−Runs two sibling storefronts most shoppers will never connect to it: SnagRx (snagrx.com) and RodeoMeds (rodeomeds.com) are the same legal entity, Modern Metabolic Medicine, Inc. SnagRx still advertises a separate $69/$119 promotion; Embody now advertises $79/$129 under its own plan menu. Neither site tells shoppers they share an operator. See our [SnagRx review](/reviews/snagrx)
−The $79/$129 figures are advertised floors tied to a selected 4-, 12-, 24- or 52-week plan, not a verified no-commitment month-to-month rate. Confirm the plan length and total before payment.
−Trustpilot rating is 3.8 / 5 across 5,305 reviews, verified August 14, 2026. Price and billing remain recurring complaint themes, although many reviews describe earlier pricing structures.
−Embody names four pharmacy partners: RedRock Pharmacy, Health Warehouse, Precision Compounding and Triad Rx. It does not state whether each prescription is filled through a 503A pharmacy or a 503B outsourcing facility. Triad Rx received a 2019 FDA warning letter for sterile-production violations; FDA closed it out in May 2023.
−No HIPAA disclosure on their site (HIPAA is the federal law protecting your medical info, most telehealth providers publish a statement confirming they follow it).
−Compounded medications only, no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic available.
−If you stop treatment and come back, Embody's doctors will likely restart you at the lowest dose (2.5mg). It's their safety policy; raise your dose history at signup, the prescriber makes the final call.

Hims

Pros

+Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+Medication starts at $149/mo for Wegovy pill, Foundayo, and Ozempic pill; Wegovy or Ozempic pens start at $199 and Zepbound at $299. The required membership makes the lowest all-in path $188 in month one and $298/mo ongoing, and exact product or dose can cost more.
+Polished app and web experience, among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.

Cons

−Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.
−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Do not confuse its $69 price with the current brand-name GLP-1 menu.
−The $149 GLP-1 figures are medication-only. A required Weight Loss Membership costs $39 in month one and $149/mo ongoing, so a $149 medication path totals at least $188 initially and $298/mo after that.
−Cash-pay only, Hims does not bill insurance, so an insured buyer may do better on a copay.
−Generic high-volume support, large patient base means less personalized attention than smaller competitors.

Our Verdict

Hims edges out Embody with a score of 7.9/10 vs 7.3/10. Published pricing is not a like-for-like monthly comparison: Embody is from $69/mo; Hims is $188 first month, then $298/mo.